Open AccessImmune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials
Author(s) -
Jissy Vijo Poulose,
Cessal Thommachan Kainickal
Publication year - 2022
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v13.i5.388
Subject(s) - medicine , nivolumab , pembrolizumab , head and neck squamous cell carcinoma , oncology , immunotherapy , clinical trial , immune checkpoint , ipilimumab , head and neck cancer , cancer
The outcomes of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) who are not candidates for local salvage therapy and of those diagnosed with recurrent or metastatic disease are dismal. A relatively new systemic therapy option that emerged in recent years in the treatment of advanced HNSCC is immunotherapy using immune checkpoint inhibitors (ICIs). The safety profile and anti-tumor activity of these agents demonstrated in early phase clinical trials paved the way to the initiation of several promising phase-3 trials in the field.